Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Geoffrey Ku, MD, summarizes the FIGHT clinical trial as presented at ASCO GI 2021

Dr. Ku, GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, tells us about bemarituzumab (an anti-FGFR2b antibody) and elaborates on results from the FIGHT study investigating bemarituzumab plus chemotherapy in the first-line treatment of gastric and gastroesophageal (GE) junction cancers as presented at the 2021 Gastrointestinal Cancers Symposium

Tags: ASCO GI Conference CoverageStomach (Gastric) Cancer

Published: 25 January 2021

Recent Videos: ASCO GI Conference Coverage

video

Geoffrey Ku, MD, summarizes the FIGHT clinical trial as presented at ASCO GI 2021

Dr. Ku, GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, tells us about bemarituzumab (an anti-FGFR2b antibody) and elaborates on ...

video

Geoffrey Ku, MD, considers the mechanism of action and future development of zanidatamab

Dr. Ku, GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, discusses zanidatamab (a bi-specific anti-HER2 antibody) and the updated data ...

video

Geoffrey Ku, MD, regarding the use of trastuzumab deruxtecan in gastric or GE junction cancer

Dr. Ku, GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, offers opinion on the FDA approval of trastuzumab deruxtecan for ...

video

Tanios Bekaii-Saab, MD, FACP, offers opinion on the updated KEYNOTE-177 as presented at ASCO GI 2021

Dr. Bekaii-Saab, Professor of Gastrointestinal Cancer, Mayo Clinical College of Medicine and Science, Vice-Chair and Section Lead, Mayo Clinic Cancer ...

video

Tanios Bekaii-Saab, MD, FACP, summarizes data regarding circulating tumor cells from ASCO GI 2021

Dr. Bekaii-Saab, Professor of Gastrointestinal Cancer, Mayo Clinical College of Medicine and Science, Vice-Chair and Section Lead, Mayo Clinic Cancer ...

video

Richard S. Finn, MD, regarding the updated IMbrave150 data from ASCO GI 2021

Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, ...

video

Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150

Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, ...

video

Richard S. Finn, MD, considers whether updated results from IMbrave150 are practice-changing

Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, ...

video

Richard S. Finn, MD, offers opinion on the role of frontline atezolizumab + bevacizumab in HCC

Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, ...

video

Richard S. Finn, MD, elaborates on promising developments in the second-line treatment of HCC

Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, ...

Related Videos

video-image

Geoffrey Ku, MD, considers the mechanism of action and future development of zanidatamab

video-image

Geoffrey Ku, MD, regarding the use of trastuzumab deruxtecan in gastric or GE junction cancer

video-image

Tanios Bekaii-Saab, MD, FACP, offers opinion on the updated KEYNOTE-177 as presented at ASCO GI 2021

video-image

Tanios Bekaii-Saab, MD, FACP, summarizes data regarding circulating tumor cells from ASCO GI 2021

video-image

Richard S. Finn, MD, regarding the updated IMbrave150 data from ASCO GI 2021

video-image

Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150

video-image

Richard S. Finn, MD, considers whether updated results from IMbrave150 are practice-changing

video-image

Richard S. Finn, MD, offers opinion on the role of frontline atezolizumab + bevacizumab in HCC

video-image

Richard S. Finn, MD, elaborates on promising developments in the second-line treatment of HCC

video-image

Namrata Vijayvergia, MD, discusses updates from the IMbrave150 trial as presented at ASCO GI 2021

video-image

Namrata Vijayvergia, MD, considers updated data from the CheckMate 040 trial in advanced HCC

video-image

Namrata Vijayvergia, MD, offers opinion on the use of FGFR inhibitors in the treatment of CCA

video-image

Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021

video-image

Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial

video-image

Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma

video-image

Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation

video-image

Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021

video-image

Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021

video-image

Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial

video-image

Zev Wainberg, MD, discusses the safety profile of bemarituzumab

video-image

Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial

video-image

Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types

video-image

Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial

video-image

Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer

video-image

Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer

video-image

Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021

video-image

Rachna Shroff, MD, elaborates on newly approved targeted therapies in esophagogastric cancer

video-image

Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer

video-image

Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers

video-image

Rachna Shroff, MD, considers the progress of targeted therapies in GI cancer

video-image

Geoffrey Y. Ku, MD, offers opinion on the practice-changing potential of the CheckMate-649 study

video-image

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

video-image

Jaffer Ajani, MD, provides opinion on the role of I-O in treatment of esophageal & gastric cancers

video-image

Zarnie Lwin, MBBS, FRACP, shares the design & outcomes of the LEAP-005 Phase II study from ESMO 2020

video-image

Howard Hochster, MD, explains the role of ramucirumab in the treatment of GE junction cancers

video-image

Alan Venook, MD, provides thoughts on the clinical progress of trastuzumab-deruxtecan in GI cancers